Pharmaceutical company Boehringer Ingelheim continued to grow in 2009, increasing its net sales by 9.7% to €12.7B from €11.6B in 2008. According to the company, this exceeded the average growth for the worldwide pharmaceutical market for the tenth year in a row, surpassing average growth by 6.7% in 2009.

Operating income, comparable to earnings before interest and tax (EBIT), rose to €2.2B.

The animal health division’s sales grew 30.6%, or 29.4% in local currency terms, to a total of €610M. Hubertus von Baumbach, who is a member of the board of managing directors and responsible worldwide for animal health, said the growth was "almost exclusively due to organic growth of our own product portfolio” rather than acquisitions from Pfizer/Wyeth.